Bulletin
Investor Alert

Intercept Pharmaceuticals Inc.

NAS: ICPT

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 16, 2022, 6:52 p.m.

/zigman2/quotes/202434567/composite

$

19.05

Change

+0.90 +4.96%

Volume

Volume 16,015

Quotes are delayed by 20 min

/zigman2/quotes/202434567/composite

Today's close

$ 17.88

$ 18.15

Change

+0.27 +1.51%

Day low

Day high

$17.57

$19.30

Open

52 week low

52 week high

$11.60

$22.36

Open

Company Description

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonal...

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Valuation

Price to Sales Ratio

1.43

Enterprise Value to EBITDA

-13.81

Enterprise Value to Sales

1.75

Efficiency

Total Asset Turnover

0.66

Liquidity

Current Ratio

3.01

Quick Ratio

3.01

Cash Ratio

2.57

Profitability

Gross Margin

96.74

Operating Margin

-15.34

Pretax Margin

-25.15

Net Margin

-25.15

Return on Assets

-16.51

Return on Total Capital

-14.45

Capital Structure

Total Debt to Total Assets

103.83

Officers and Executives

Name Age Officer Since Title
Mr. Jerome B. Durso 53 2017 President, Chief Executive Officer & Director
Mr. Bryan Ball 51 2021 Chief Quality Officer
Mr. Andrew Saik 51 2021 Chief Financial Officer
Dr. M. Michelle Berrey 54 2021 Chief Medical Officer
Dr. Gail Cawkwell 59 - SVP-Medical Affairs, Safety & Pharmacovigilance

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/01/2022 Jared M. Freedberg
General Counsel
771   Derivative/Non-derivative trans. at $15.71 per share. 12,112
04/11/2022 Bryan Ball
Chief Qual. Officer & SVP Ops.
531   Derivative/Non-derivative trans. at $17.19 per share. 9,127
02/15/2022 Linda M. Richardson
EVP & Chief Commercial Officer
171   Derivative/Non-derivative trans. at $15.93 per share. 2,724
02/14/2022 Linda M. Richardson
EVP & Chief Commercial Officer
529   Derivative/Non-derivative trans. at $14.85 per share. 7,855
02/12/2022 Gail Cawkwell
SVP, Med Affairs, Safety & PV
320   Derivative/Non-derivative trans. at $15.8 per share. 5,056
02/01/2022 Jared M. Freedberg
General Counsel
4,072   Derivative/Non-derivative trans. at $16.91 per share. 68,857
01/27/2022 Jerome B. Durso
President & CEO; Director
35,700   Award at $0 per share. 0
01/27/2022 M. Michelle Berrey
President, R&D and CMO
10,300   Award at $0 per share. 0
01/27/2022 Andrew Saik
EVP & Chief Financial Officer
10,300   Award at $0 per share. 0
01/27/2022 Jared M. Freedberg
General Counsel
10,300   Award at $0 per share. 0
01/27/2022 Gail Cawkwell
SVP, Med Affairs, Safety & PV
6,600   Award at $0 per share. 0
01/27/2022 Linda M. Richardson
EVP & Chief Commercial Officer
10,300   Award at $0 per share. 0
01/27/2022 David Ford
Chief Human Resources Officer
6,600   Award at $0 per share. 0
01/27/2022 Bryan Ball
Chief Qual. Officer & SVP Ops.
3,600   Award at $0 per share. 0
01/27/2022 Rocco Venezia
Chief Accounting Officer
3,600   Award at $0 per share. 0
01/11/2022 Bryan Ball
Chief Qual. Officer & SVP Ops.
2,455   Derivative/Non-derivative trans. at $16.83 per share. 41,317
01/01/2022 Jerome B. Durso
President & CEO; Director
334   Derivative/Non-derivative trans. at $16.29 per share. 5,440
01/01/2022 David Ford
Chief Human Resources Officer
106   Derivative/Non-derivative trans. at $16.29 per share. 1,726
01/01/2022 Rocco Venezia
Chief Accounting Officer
35   Derivative/Non-derivative trans. at $16.29 per share. 570
12/31/2021 Jerome B. Durso
President & CEO; Director
5,607   Derivative/Non-derivative trans. at $16.29 per share. 91,338
12/31/2021 Gail Cawkwell
SVP, Med Affairs, Safety & PV
2,455   Derivative/Non-derivative trans. at $16.29 per share. 39,991
12/31/2021 Linda M. Richardson
EVP & Chief Commercial Officer
1,211   Derivative/Non-derivative trans. at $16.29 per share. 19,727
12/31/2021 David Ford
Chief Human Resources Officer
1,606   Derivative/Non-derivative trans. at $16.29 per share. 26,161
12/31/2021 Rocco Venezia
Chief Accounting Officer
515   Derivative/Non-derivative trans. at $16.29 per share. 8,389
12/31/2021 Lisa M. DeFrancesco
SVP, IR & Corp. Affairs
542   Derivative/Non-derivative trans. at $16.29 per share. 8,829
/news/latest/company/us/icpt

MarketWatch News on ICPT

  1. Intercept Pharmaceuticals stock price target cut to $31 from $43 at Canaccord Genuity

    9:22 a.m. Aug. 3, 2021

    - Tomi Kilgore

  2. The FDA's Biogen Decision Will Cause Waves Across Biotech

    9:20 p.m. June 1, 2021

    - Barron's Online

  3. Intercept Pharmaceuticals downgraded to neutral from buy at B. Riley

    7:23 a.m. May 26, 2021

    - Tomi Kilgore

  4. Intercept Pharmaceuticals stock price target cut to $74 from $97 at B. Riley FBR

    8:28 a.m. Nov. 20, 2020

    - Tomi Kilgore

  5. Intercept Pharmaceuticals upgraded to outperform from market perform at Raymond James

    8:47 a.m. Nov. 10, 2020

    - Tomi Kilgore

  6. Intercept shares gain after it announces layoffs

    8:19 a.m. Sept. 2, 2020

    - Jaimy Lee

  7. A Top Contender Drops Out of Race for a NASH Drug

    11:15 a.m. July 23, 2020

    - Barron's Online

  8. Biogen Submits Troubled Alzheimer’s Drug for FDA Approval

    12:07 p.m. July 8, 2020

    - Barron's Online

  9. Analysts Are Downgrading Intercept Pharmaceuticals. Here’s Why.

    11:53 a.m. June 30, 2020

    - Barron's Online

  10. Intercept Pharmaceuticals downgraded to market perform at BMO Capital

    9:07 a.m. June 30, 2020

    - Tomi Kilgore

  11. Intercept Pharmaceuticals stock price target cut to $97 from $158 at B. Riley FBR

    7:53 a.m. June 30, 2020

    - Tomi Kilgore

  12. Intercept Pharmaceuticals stock price target cut to $50 from $89 at SVB Leerink

    6:11 a.m. June 30, 2020

    - Tomi Kilgore

  13. Intercept Shares Tumble on NASH Disappointment

    4:05 p.m. June 29, 2020

    - Barron's Online

  14. Intercept's stock plunges 35% premarket after receiving CRL from FDA for treatment of fibrosis due to NASH

    7:17 a.m. June 29, 2020

    - Tomi Kilgore

  15. Intercept Pharmaceuticals receives FDA letter for its treatment for fibrosis due to NASH

    7:15 a.m. June 29, 2020

    - Ciara Linnane

  16. Intercept Pharmaceuticals shares slide 35% premarket

    7:15 a.m. June 29, 2020

    - Ciara Linnane

  17. Loading more headlines...
/news/nonmarketwatch/company/us/icpt

Other News on ICPT

  1. 10-Q: INTERCEPT PHARMACEUTICALS, INC.

    4:08 p.m. May 6, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  2. BRCC and CYN among mid-day movers

    1:02 p.m. May 5, 2022

    - Seeking Alpha

  3. Intercept Pharma Q1 2022 Earnings Preview

    12:06 p.m. May 5, 2022

    - Seeking Alpha

  4. Notable earnings before Friday's open

    10:41 a.m. May 5, 2022

    - Seeking Alpha

  5. Madrigal: Clear Path Ahead

    2:09 p.m. April 22, 2022

    - Seeking Alpha

  6. Loading more headlines...

At a Glance

Intercept Pharmaceuticals, Inc.

305 Madison Avenue

Morristown, New Jersey 07960

Phone

1 6467471000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$363.47M

Net Income

$-91.43M

Employees

437.00

/news/pressrelease/company/us/icpt

Press Releases on ICPT

  1. Loading more headlines...
Link to MarketWatch's Slice.